Please try another search
Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation. The company’s delivery technology MeltDose is designed to enhance the absorption and bioavailability. Its lead product candidate is Envarsus XR, a once-daily dosage tablet version of tacrolimus, which is used to aid in the prophylaxis of organ rejection in kidney transplant patients. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is based in Copenhagen, Denmark. As of January 14, 2020, Veloxis Pharmaceuticals A/S operates as a subsidiary of Asahi Kasei Pharma Denmark A/S.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review